aMoon’s second healthtech fund tops out at $750 million

The Marius Nacht led fund raised an additional $90 million from Credit Suisse and other major institutional investors in Israel and abroad

Hagar Ravet 12:0222.07.20
Israel-based life sciences venture capital firm aMoon’s second fund has reached $750 million in commitments. In March 2019, the fund that was founded by Marius Nacht, the co-founder of firewall pioneer Check Point Software Technologies Ltd., announced it had raised a total of $660 million. The additional $90 million announced now brings aMoon II, which focuses on investments in companies that are in advanced stages, to its maximum allowed cap.


aMoon named Credit Suisse among the central investors in the fund, who led the round together with the VC firm as part of their strategic partnership. The round included new commitments from previous investors both Israeli and international, including additional major institutional investors, as well as commitments by new investors from the U.S., Australia, Latin America, and Europe.


aMoon co-founders Yair Schindel (left) and Marius Nacy. Photo: PR aMoon co-founders Yair Schindel (left) and Marius Nacy. Photo: PR
So far the fund has invested $200 million in nine companies. The fund specializes in the domains of pharma, digital health, and medical technology, making investments in the range of $10 million to $50 million.


aMoon was founded in 2016 by Nacht and Dr. Yair Schindel, the former CEO of an Israeli government agency in charge of pushing forward digital initiatives, who now runs the fund.


“This round is a significant testimony to the faith international investors have in the Israeli healthtech ecosystem, particularly amid the global coronavirus crisis,” said Schindel. “While the crisis created uncertainty and disrupted markets and industries everywhere, it also expedited new technological innovation processes in the medical industry and it is clear that Israel’s healthech sector is a leading global player. aMoon and other strong Israeli funds must continue to bridge between the local ecosystem and the international one and expedite early detection and treatment using groundbreaking innovation.”